Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Hepatitis C Virus NS3 Helicase Inhibitor Discovery.

Li K, Frankowski KJ, Hanson AM, Ndjomou J, Shanahan MA, Mukherjee S, Kolli R, Shadrick WR, Sweeney NL, Belon CA, Neuenswander B, Ferguson J, Aubé J, Schoenen FJ, Blagg BSJ, Frick DN.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Mar 14].

2.

Benzothiazole and Pyrrolone Flavivirus Inhibitors Targeting the Viral Helicase.

Sweeney NL, Hanson AM, Mukherjee S, Ndjomou J, Geiss BJ, Steel JJ, Frankowski KJ, Li K, Schoenen FJ, Frick DN.

ACS Infect Dis. 2015 Mar 13;1(3):140-148.

3.

A macrocyclic HCV NS3/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target.

Schiering N, D'Arcy A, Villard F, Simic O, Kamke M, Monnet G, Hassiepen U, Svergun DI, Pulfer R, Eder J, Raman P, Bodendorf U.

Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21052-6. doi: 10.1073/pnas.1110534108. Epub 2011 Dec 12.

4.

Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication.

Mukherjee S, Weiner WS, Schroeder CE, Simpson DS, Hanson AM, Sweeney NL, Marvin RK, Ndjomou J, Kolli R, Isailovic D, Schoenen FJ, Frick DN.

ACS Chem Biol. 2014 Oct 17;9(10):2393-403. doi: 10.1021/cb500512z. Epub 2014 Aug 15.

5.

Optimization of potent hepatitis C virus NS3 helicase inhibitors isolated from the yellow dyes thioflavine S and primuline.

Li K, Frankowski KJ, Belon CA, Neuenswander B, Ndjomou J, Hanson AM, Shanahan MA, Schoenen FJ, Blagg BS, Aubé J, Frick DN.

J Med Chem. 2012 Apr 12;55(7):3319-30. doi: 10.1021/jm300021v. Epub 2012 Mar 22.

6.

Fluorescent primuline derivatives inhibit hepatitis C virus NS3-catalyzed RNA unwinding, peptide hydrolysis and viral replicase formation.

Ndjomou J, Kolli R, Mukherjee S, Shadrick WR, Hanson AM, Sweeney NL, Bartczak D, Li K, Frankowski KJ, Schoenen FJ, Frick DN.

Antiviral Res. 2012 Nov;96(2):245-55. doi: 10.1016/j.antiviral.2012.08.006. Epub 2012 Aug 25.

7.

Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle.

McGivern DR, Masaki T, Lovell W, Hamlett C, Saalau-Bethell S, Graham B.

J Virol. 2015 May;89(10):5362-70. doi: 10.1128/JVI.03188-14. Epub 2015 Mar 4.

9.

Abrogation of hepatitis C virus NS3 helicase enzymatic activity by recombinant human antibodies.

Artsaenko O, Tessmann K, Sack M, Häussinger D, Heintges T.

J Gen Virol. 2003 Sep;84(Pt 9):2323-32.

PMID:
12917452
10.

Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase.

Furuta A, Tsubuki M, Endoh M, Miyamoto T, Tanaka J, Salam KA, Akimitsu N, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Sekiguchi Y, Tsuneda S, Noda N.

Int J Mol Sci. 2015 Aug 7;16(8):18439-53. doi: 10.3390/ijms160818439.

11.

pH-dependent conformational changes in the HCV NS3 protein modulate its ATPase and helicase activities.

Ventura GT, Costa EC, Capaccia AM, Mohana-Borges R.

PLoS One. 2014 Dec 31;9(12):e115941. doi: 10.1371/journal.pone.0115941. eCollection 2014.

12.
13.

Identification and analysis of hepatitis C virus NS3 helicase inhibitors using nucleic acid binding assays.

Mukherjee S, Hanson AM, Shadrick WR, Ndjomou J, Sweeney NL, Hernandez JJ, Bartczak D, Li K, Frankowski KJ, Heck JA, Arnold LA, Schoenen FJ, Frick DN.

Nucleic Acids Res. 2012 Sep 1;40(17):8607-21. Epub 2012 Jun 27.

15.

Inhibition of hepatitis C virus replication and viral helicase by ethyl acetate extract of the marine feather star Alloeocomatella polycladia.

Yamashita A, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Fujita Y, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Tanaka J, Moriishi K.

Mar Drugs. 2012 Apr;10(4):744-61. doi: 10.3390/md10040744. Epub 2012 Mar 28.

16.

Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.

Lee S, Yoon KD, Lee M, Cho Y, Choi G, Jang H, Kim B, Jung DH, Oh JG, Kim GW, Oh JW, Jeong YJ, Kwon HJ, Bae SK, Min DH, Windisch MP, Heo TH, Lee C.

Br J Pharmacol. 2016 Jan;173(1):191-211. doi: 10.1111/bph.13358. Epub 2015 Nov 25.

17.

Designing and analysis of a potent bi-functional aptamers that inhibit protease and helicase activities of HCV NS3.

Umehara T, Fukuda K, Nishikawa F, Sekiya S, Kohara M, Hasegawa T, Nishikawa S.

Nucleic Acids Symp Ser (Oxf). 2004;(48):195-6.

PMID:
17150545
18.

Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3.

Umehara T, Fukuda K, Nishikawa F, Kohara M, Hasegawa T, Nishikawa S.

J Biochem. 2005 Mar;137(3):339-47.

PMID:
15809335
19.

Isolation of specific and high-affinity RNA aptamers against NS3 helicase domain of hepatitis C virus.

Hwang B, Cho JS, Yeo HJ, Kim JH, Chung KM, Han K, Jang SK, Lee SW.

RNA. 2004 Aug;10(8):1277-90. Epub 2004 Jul 9.

20.

Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity.

Phalaphol A, Thueng-In K, Thanongsaksrikul J, Poungpair O, Bangphoomi K, Sookrung N, Srimanote P, Chaicumpa W.

J Virol Methods. 2013 Dec;194(1-2):289-99. doi: 10.1016/j.jviromet.2013.08.032. Epub 2013 Sep 12.

PMID:
24036073

Supplemental Content

Support Center